


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) An 1-[(indol-3-yl)carbonyl]piperazine derivative having the general formula I



RECEIVED
CENTRAL FAX CENTER

DEC 05 2006

Formula I

wherein

R represents 1-4 substituents independently selected from H, (C₁₋₄)alkyl (optionally substituted with halogen), (C₁₋₄)alkyloxy (optionally substituted with halogen), halogen, OH, NH₂, CN and NO₂;

R₁ is (C₅₋₈)cycloalkyl or (C₅₋₈)cycloalkenyl;

R₂ is H, methyl or ethyl;

R₃, R_{3'}, R₄, R_{4'}, R₅, R₆ and R_{6'} are independently hydrogen or (C₁₋₄)alkyl, optionally substituted with (C₁₋₄)alkyloxy, halogen or OH;

R₆ is hydrogen or (C₁₋₄)alkyl, optionally substituted with (C₁₋₄)alkyloxy, halogen or OH; or
R₆ forms together with R₇ a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S;

R₇ forms together with R₆ a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S; or

R₇ is H, (C₁₋₄)alkyl or (C₃₋₅)cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C₁₋₄)alkyloxy; or

a pharmaceutically acceptable salt thereof.

2. (Original) The 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R₂ is H and R₁ is (C₅₋₈)cycloalkyl.

3. (Original) The 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein R is (C₁₋₄)alkyloxy or halogen.

4. (Original) The 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 3, wherein R represents a methoxy group at the 7-position of the indole ring.

5. (Original) The 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 4, wherein R₃, R_{3'}, R_{4'}, R₅, R_{5'} and R₆ are H; R₄, R₆ and R₇ are independently H or (C₁₋₄)alkyl; or R₆ forms together with R₇ a 5- or 6-membered saturated heterocyclic ring and R₄ is H or (C₁₋₄)alkyl.

6. (Previously Presented) The 1-[(indol-3-yl)carbonyl]piperazine derivative according to claim 1, wherein the derivative is selected from the group consisting of

1-[(1-(cyclohexylmethyl)-7-methoxy-1H-indol-3-yl)carbonyl]-3,5-dimethyl-4-ethylpiperazine;

1-[(1-(cyclohexylmethyl)-7-methoxy-1H-indol-3-yl)carbonyl]-3,4,5-trimethylpiperazine;

(S)-1-[(1-(cyclohexylmethyl)-7-methoxy-1H-indol-3-yl)carbonyl]-3,4-dimethylpiperazine;

(S)-2-[(1-(cyclohexylmethyl)-7-methoxy-1H-indol-3-yl)carbonyl]-octahydro-2H-pyrido-[1,2-a]pyrazine;

(S)-2-[(1-(cyclohexylmethyl)-7-methoxy-1H-indol-3-yl)carbonyl]-octahydro-2H-pyrrolo-[1,2-a]pyrazine; and

(S)-2-[(1-(cyclopentylmethyl)-7-methoxy-1H-indol-3-yl)carbonyl]-octahydro-2H-pyrido-[1,2-a]pyrazine;

or a pharmaceutically acceptable salt thereof of each individual derivative.

7. (Canceled).

8. (Previously Presented) A pharmaceutical composition, comprising:

the 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, and

a pharmaceutically acceptable carrier.

9. (Canceled).

10. (Canceled)

Serial No. 10/518,279

11. (Previously Presented) A method of treating pain in a patient in need thereof, comprising:
administering an effective amount of the derivative according to claim 1.